We’re Hiring! View Open Positions

  • About Us
    • Leadership
    • Enzyvant Values
  • Area of Focus
  • Product & Support
  • Stories
  • Careers
  • Newsroom
  • Contact Us

← Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

enz

By Brendan Egan | Published October 8, 2021 | Full size is 1430 × 847 pixels

Bookmark the permalink.

Contact us for more information

Contact Us

© 2022 Enzyvant Therapeutics GmbH. All rights reserved. ENZYVANT is a registered trademark and the Enzyvant Logo is a trademark of Enzyvant Therapeutics GmbH.

  • Privacy Policy
  • Terms and Conditions
  • Community Guidelines
  • Compliance
  • US–2000022
  • US-2100063

please enter to bigin your search.